Hamlet BioPharma (HAMLET) Q4 2024 earnings summary

Executive summary

• Fiscal year 2023-2024 marked by strong clinical progress in cancer and infection therapeutics, including FDA IND clearance and Fast Track status for Alpha1H in bladder cancer.

• Merger with SelectImmune Pharma expanded the project portfolio and led to a new company name, Hamlet BioPharma AB.

• Strategic alliances and commercial collaborations initiated to support partnering and asset development.

Financial highlights

• Net sales were SEK 0 for both the quarter and full year; other operating income SEK 30k (full year), down from SEK 2,421k.

• Group loss before tax for the year was SEK -41,817k, compared to SEK -20,441k year-over-year.

• Loss per share for the year was SEK -0.2493, compared to SEK -0.1824 year-over-year.

• Equity/assets ratio improved to 94.0% from 73.5% year-over-year.

• Cash and cash equivalents at year-end were SEK 23,101k, up from SEK 18,393k.

Outlook and guidance

• Continued focus on advancing Alpha1H towards Phase III trials and expanding immunotherapy pipeline.

• Additional capital will be needed in the next financial year to secure ongoing operations.